NRXS: Strong insurance coverage and clinical data position the company for rapid growth through 2027
The conference featured a med tech company pioneering neuromodulation therapies for GI disorders, with strong insurance coverage, robust clinical evidence, and rapid revenue growth. Expansion of payer coverage and sales force are expected to drive exponential growth through 2027.Based on Neuraxis…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.